Member Info for MarquessR

I thought I saw a break out at 1.124 this morning. Suffice to say I was wrong.

Whilst looking for the specifics of the Q1 results due on the 28/04, I noted that GSK have posted a spreadsheet called 'Respiratory and HIV product sales reporting changes'

It appears to have a clear break down of FY 2020 sales for the aforementioned drugs. Shows the growth in revenue from Juluca and Dovato, manufactured by Janssen and Viir respectively. I think some people posting previously were looking for GSK to make this point?

Link - https://www.gsk.com/en-gb/investors/quarterly-results/

Too soon CSDI, too soon.

Sigh.

I think the lizard people have a controlling stake TBH.

Thanks Pokerchips, that does make some sense.

Despite having stared at the pending divi payment in my brokerage account for the last couple of weeks my brain failed to link the two. Doh!

Is there anyone who utilises the TA approach with a data led reason for this £13 barrier. Or are we just looking at a psychological barrier?

Feels like we have been bumping off this level for a couple of weeks, but no further significant drops either on the plus side.

CEO & Executive Director exercised options to buy UK£1.1m worth of stock.

On the 31st of March, Zoran Bogdanovic exercised 48.83k options to receive shares at no cost, then sold around 2.85k of them at UK£23.32 each and kept the remainder.

Since June 2020, Zoran's direct individual holding has increased from 300.58k shares to 305.44k.
Company insiders have collectively bought UK£2.1m more than they sold, via options and on-market transactions, in the last 12 months.

News report from Simply Wall St.

Good news in my book, but Q1 / Q2 this year might be hard, expecting a possible SP drop on financial results given the current COVID issues in Europe. Would be a strong buy if re head back down towards the 20 GBP mark.

Peaking over 1300 today! Id say a buy, if i had not already spent all my money on it already.

I think better news for Redrow was the 5% mortgage support coming from the Gov.

CercleFinance.com) - The broker has increased its target price for the share by 16% to 1,200 p (from 1,032 p) and has confirmed its Outperform rating on the stock.

'Sector laggard with the greatest potential to improve investor perception: it continues to lag the sector in value recovery considering both its market cap and EV,' Credit Suisse says

'We reflect this and raise 2023E-2024E PBT by 5-6%. Our analysis of EZJ's valn relative to the rest of the sector, and new analysis of competitive positioning drives a 16% uplift to our target price to 1,200p and we re-iterate OP'.

Copyright (c) 2021 CercleFinance.com. All rights reserved.

I have a position in EZJ.

Short to mid term, i don't see a breach of pre COVID highs. Increased debt, decreased number of flights / customers, increased costs (I am assuming this to be the case).

Short term I am expecting some growth, possibly a best into the low teens, feeding off the joy of release. I will sell out at that point, in expectation of a drop into Q3 / Q4 2021. Obviously if you are long term bullish then there is probably growth to come out the other side, into 2022, but I would rather eye a new entry point over the winter.

I posted about this on the 17th

https://www.lse.co.uk/ShareChat.asp?ShareTicker=GSK&share=Glaxosmithkline&page=6&thread=42031C0D-58FC-434B-A462-BB499A970FF7

They note in their end of year reporting the underperformance of Pharma but still loaded up.

Battleja- thanks for taking the time to reply, it is appreciated!

I hadn’t heard of the z-score before. I will add it to my reading list.

I am also long GSK and it’s already got too big a position within my portfolio, but at these prices I’m still considering adding more.

Must resist the urge and go and spend my money on something else that will drop in a slightly different pattern. Off to ULVR I go, haha.

BattleJa - do you know the criteria / requirements for such a rating to apply?

I note the raised concerns about the dividend cut, planned business split and current impact of COVID on profits. But to read a suggestion of a higher percentage chance of predicted bankruptcy sounds a little over cooked?!

Unless I’ve missed something significant from the EOY results.

Greetings all.

This morning I was reviewing the Simply Wall St return for GSK. The one section that caught my eye today was the GSK Top Shareholders report.

The top five shareholders are listed as follows;

Ownership / Name / Shares / Current Value / Change % / Portfolio %

6.91% / BlackRock, Inc. / 344,818,951 / £4.4b / -2.05% / 0.13%
4.96% / Capital Research and Management Company - 247,719,834 / £3.2b / -17.06% / 0.24%
3.85% / The Vanguard Group, Inc. / 192,023,859 / £2.4b / 1.09% / 0.07%
3.77% / Dodge & Cox / 188,190,716 / £2.4b / 24.41% / 1.89%
2.88% / State Street Global Advisors, Inc. / 143,948,549 / £1.8b / 1.36% / 0.14%

Dodge & Cox stands out for the large increase in holdings over the last Q.

There website only lists 3 funds - Global Stocks / US Stocks / Global Bonds
Source - https://www.dodgeandcoxworldwide.com/ourfunds.asp

The fact sheet for the Global Stocks fund carries the following entry

'Key Detractors - Weaker relative returns from holdings in the Health Care sector (up 5% compared to up 7% for the MSCI World sector) hurt results. Sanofi, GlaxoSmithKline, and Alnylam Pharmaceuticals detracted.'

Source - https://www.dodgeandcoxworldwide.com/pdf/shareholder_reports/dc_ww_global_stock_fact_sheet.pdf

So they have recognised the poor results from GSK this year, but still loaded up on shares. A bullish sign from Dodge & Cox or am I missing something?

Marquess R.

Somewhat of a Redrow result for BATS! FTSE100 listings don't seem to be able to catch a break at the moment.

I’m no expert, but I think it was something to do with the strong run up prior to results.

The general consensus prior to results was really positive, and the SP followed than enthusiasm.

I see the SP hit £5.80 before today’s drop, I don’t know what the volumes looked like but possibly significant selling to take profit?

Pull back to the 1 month view and I like the direction and momentum.

Toff,

RE Simply Wall Street and their ‘articles’, I use the free version of their portfolio tracking, and I find all the business reports and articles need to be taken with a pinch of salt.

Are far as I can tell they are all automatically generated by computer based on the financial stats with an absolute minimum of human review or edits, they take 0 account of the wider financial picture such as QE, FX, world affairs and the such.

Maybe we can ask the BoD to take a field trip to CCH HQ!

They posted a FY loss (but a minor dividend growth) and the market can’t get enough at the moment. Plenty of enthusiasm in their EOY report!

Papucel

In regards to your comment about sanity, the following quote springs to mind;

‘Individuals who cannot master their emotions are ill-suited to profit from the investment process.’ - Benjamin Graham.

Not in any was as a dig, but entirely as aspiration.

Are a lot of people in the red on GSK now - oh yes.
Is GSK SP only going down for ever - I imagine very unlikely.
Can I wait - Yes. Okay good, no problem.

Sure you could sell at a loss and try your luck elsewhere, but the core business of GSK is solid, it’s just out of favour at the moment, for a variety of reasons both legitimate and bull****.

This is just my opinion and I am a stranger on the internet.